Skip to content

Moxibustion for Treating Cancer-related fatigue

Moxibustion for Treating Cancer-related fatigue: A Randomized, Placebo-controlled, Pilot Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0000918
Enrollment
30
Registered
2013-11-12
Start date
2013-11-18
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device, Procedure/Surgery : Treatment in each groups will be conducted by doctors of Korean medicine (DKMs) at least four years of clinical experience according to pre-specified protocol and S

Sponsors

Korea Institute of Oriental Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Both male and female, 19 years of age and older with a diagnosis of cancer 2. Had completed cancer-related treatments (e.g. surgery, chemotherapy, radiotherapy, immunotherapy, except for on-going hormone therapy, which must have been initiated at least 3 weeks prior to enrollment) at least 12 weeks 3. A score = 4 on the Brief Fatigue Inventory (BFI) at least 4 weeks before the randomization 4. A score = 2 on the Eastern Cooperative Oncology Group (ECOG) performance status

Exclusion criteria

Exclusion criteria: 1. A platelet count less than 50,000/ µL, Hemoglobin less than 9g/d, Hematocrit less than 30%; 2. Receiving aggressive treatment for anemia (e.g. erythropoietin or blood transfusion); 3. A score = 11 on HADS (Hospital Anxiety and Depression Scale); 4. Taking medicine for depression; 5. A score = 4 on the Numeric rating scale(NRS) for cancer pain 6. ANC (Absolute neutrophil count) = 1,000; 7. Had similar fatigue prior to diagnosis of cancer 8. Had an anticipated survival rate of less than six months 9. Have a plan of surgery, chemotherapy, radiotherapy during the study 10. Medication (e.g. stimulant) or Korean medical treatment (e.g. acupuncture, moxibustion, cupping or herbal medicine) for cancer-related fatigue used within the past two weeks 11. Have a new plan of change of chronic medications or initiation of dietary supplements or non-phamacologic therapy (e.g. exercise, meditation, cognitive behavioral therapy etc.) during the study 12. Known hypersensitivity reactions or severe adverse events after moxibustion treatment or an inability to cooperate with moxibustion treatment by some reasons, especially difficulty in breathing. 13.Pregnancy, planning a pregnancy or breast-feeding 14. In the case that researcher determined participants are inappropriate in clinical trial in the light of clincal symptoms or blood test

Design outcomes

Primary

MeasureTime frame
Brief fatigue inventory (BFI)

Secondary

MeasureTime frame
Brief fatigue inventory (BFI);Fatigue Questionnaire (FQ);Functional Assessment of Cancer Therapy-Fatigue (FACT-F) ;Hospital Anxiety and Depression Scale (HADS);Pittsburgh Sleep Quality Index (PSQI);EORTC QLQ-C30;Days of restricted activity;Patients' Global Impression of Change (PGIC) ;Serum immunological, oxidative and antioxidative marker;Adverse events

Countries

Korea, Republic of

Contacts

Public ContactSeunghoon Lee

Korea Institute of Oriental Medicine

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026